Aperam and United States Antimony Compared on Financial Metrics

1 report, 1 independent Updated Wed 00:00

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A comparison of Aperam and United States Antimony revealed that Aperam has higher revenue and earnings than United States Antimony. While United States Antimony trades at a lower price-to-earnings ratio, Aperam has higher revenue and earnings per share. Aperam has a beta of 1.34, indicating higher volatility than the S&P 500, compared to United States Antimony's beta of 0.38.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differing financial profiles between the two materials companies, including valuation, profitability, and risk. These metrics influence investment decisions regarding the materials sector.

From themarketsdaily.com

Who's involved

AperamMaterials company whose financial metrics and operational locations are being compared.
ValeMultinational diversified metals and mining corporation that competes in the materials market.
CitigroupInvestment bank that issued a neutral market rating on Aperam.
EuropeContinent where Aperam operates facilities and is subject to market conditions.
Minas GeraisState in Brazil where Aperam manages a stainless plant and eucalyptus plantations.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

ValeSpeculative
Vale might see changes in market demand for materials if investment sentiment shifts toward Aperam or United States Antimony.
AperamSpeculative
Aperam's operations in Europe could affect its regulatory costs and market access.

Coverage

Newest first; wire copies grouped

Wed 00:00themarketsdaily.com